Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Disitamab Vedotin|DRUG: Toripalimab
Sponsor: RemeGen Co., Ltd.